🧠 This Week in Neuroscience: Apertura Gene Therapy, Boston AI Tool, PharmaTher’s FDA Approval and More
Stay informed with the latest neuroscience breakthroughs! In this video, we dive into the most recent advancements in Alzheimer’s, multiple sclerosis, Dravet syndrome, and more. From innovative gene therapies and AI-powered diagnostic tools to FDA-approved treatments and expanding clinical trials, this week’s updates cover it all:
📌 What’s Inside This Week’s Update
🚀 Apertura Gene Therapy partners for CNS treatments with novel capsid technology
🧠 Boston University AI tool aids in early Alzheimer’s detection
🧬 ProMIS Neurosciences advancing Alzheimer’s therapies with FDA Fast Track designation
🩸 T-NeuroDx secures NIH grant for early Alzheimer’s biomarker research
💊 OM1 expands neurology network to 3 million patients
🌟 PharmaTher gets FDA approval for ketamine (KETARx™) in pain management
⚡ Stoke Therapeutics and Biogen start Phase 3 trial for Dravet syndrome
🧪 Quantum BioPharma prepares for Phase 2 MS trial with oral formulation
💼 AbbVie invests $195M to expand U.S. manufacturing
🧬 Neurizon Therapeutics begins first NUZ-001 batch manufacturing for NDA submission
🌍 SineuGene ALS gene therapy cleared for global trials in China & U.S.
📢 Stay Ahead in Neuroscience Research!
✅ Like, share, and subscribe for weekly updates on neuroscience and breakthrough therapies!
#Neuroscience #Alzheimers #MultipleSclerosis #GeneTherapy #Biotech #FDAApproval #ClinicalTrials #NeurodegenerativeDiseases #HealthcareInnovation #LucidQuest